Clinical Trials Logo

Calcific Uremic Arteriolopathy clinical trials

View clinical trials related to Calcific Uremic Arteriolopathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT04592640 Active, not recruiting - Clinical trials for Chronic Kidney Diseases

Stem Cells for Uremic Calciphylaxis Patients

Start date: September 17, 2018
Phase: N/A
Study type: Interventional

Treatment for Uremic Calciphylaxis Patients with Human Amniotic Mesenchymal Stem Cells

NCT ID: NCT04195906 Completed - Calciphylaxis Clinical Trials

Phase 3 Study of SNF472 for Calciphylaxis

Calciphyx
Start date: February 12, 2020
Phase: Phase 3
Study type: Interventional

The primary objectives are to assess the efficacy, safety, and tolerability of SNF472 compared to placebo when added to background care for the treatment of calciphylaxis (CUA).

NCT ID: NCT03032835 Recruiting - Clinical trials for Chronic Kidney Diseases

Partners Calciphylaxis Biobank

PCB
Start date: January 2017
Phase:
Study type: Observational [Patient Registry]

Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles. There are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pathobiology, rare incidence and lack of collaborative approach have been some of the major limiting factors towards treating calciphylaxis. The Partners Calciphylaxis Biorepository (PCB) aims to address these gaps within calciphylaxis research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for a calciphylaxis repository.

NCT ID: NCT02790073 Completed - Calciphylaxis Clinical Trials

Phase 2 Study With SNF472 in Calciphylaxis Patients

Start date: May 2016
Phase: Phase 2
Study type: Interventional

To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).

NCT ID: NCT02527213 Terminated - Calciphylaxis Clinical Trials

Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopath

Start date: January 30, 2015
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of Sodium Thiosulfate (STS) compared to placebo, in reducing analgesic requirement in subjects with calcific uremic arteriolopathy (CUA) during an initial 28-day treatment phase.

NCT ID: NCT02278692 Completed - Calciphylaxis Clinical Trials

Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy

VitK-CUA
Start date: March 2015
Phase: N/A
Study type: Interventional

Calcific uremic arteriolopathy a.k.a. calciphylaxis is a vascular calcification disorder seen in dialysis patients. Calcific uremic arteriolopathy has 60-80% one-year mortality and significant morbidity associated with non-healing and extremely painful skin lesions. At present, there is no effective treatment for calcific uremic arteriolopathy. Vitamin K is an important vitamin for inhibiting vascular calcification. It is known to increase the circulating levels of carboxylated Matrix Gla Protein, a potent inhibitor of vascular calcification. However, the effects of vitamin K supplementation in patients with calcific uremic arteriolopathy are unknown. The purpose of this study is to conduct a pilot randomized controlled trial to examine the effects of oral vitamin K supplementation on circulating levels of anti-calcification factor (carboxylated Matrix Gla Protein) and clinical outcomes in patients with calcific uremic arteriolopathy.